Meta AnalysisID 4320
丹参酮IIA磺酸钠治疗冠心病的有效性和安全性：随机临床试验的系统评价和Meta分析
CRD42021277465
（1）Population: patients with coronary heart disease, including unstable angina pectoris, acute myocardial infarction, stable angina pectoris and perioperative interventional patients. （2）Intervention and control: the tre
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4320
- Evidence Id
- 12878
- Core Evidence Id
- 12878
- Source Meta Analysis Id
- 4288
- Herb2 Meta Analysis Id
- HBMA004288
- Crd Id
- CRD42021277465
- Title
- Effectiveness and safety of sodium tanshinone IIA sulfonate in patients with coronary heart disease: a systematic review and meta-analysis of randomized clinical trials
- Review Question
- （1）Population: patients with coronary heart disease, including unstable angina pectoris, acute myocardial infarction, stable angina pectoris and perioperative interventional patients. （2）Intervention and control: the treatment group was sodium tanshinone IIA sulfonate(STS) combined with conventional Western medicine treatment, and the control group was conventional Western medicine treatment, without any Traditional Chinese Medicine/Proprietary Chinese Medicine preparation, with or without placebo. There are two comparison groups: 1) STS + conventional Western medicine treatment VS conventional Western medicine treatment; 2) STS + conventional Western medicine treatment VS placebo + conventional Western medicine treatment. （3）Outcomes: 1) As for unstable angina pectoris, stable angina pectoris and perioperative interventional patients, we will extract the following outcomes：clinical curative effect, angina pectoris curative effect, electrocardiogram curative effect, attack frequency of angina pectoris, duration of angina pectoris, myocardial injury markers (troponin-I, CK, CK - MB) and blood rheology indexes (whole blood high shear viscosity, plasma viscosity, whole blood low shear viscosity, erythrocyte hematocrit, platelet maximum aggregation rate, fibrinogen), inflammation index (conventional CRP, hs-CRP, interleukin-6), blood lipid indicators (TC, TG, HDL-L, LDL-L), incidence of major adverse cardiovascular events, incidence of adverse events. 2) As for acute myocardial infarction, we will extract the following outcomes：heart pump function (left ventricular ejection fraction, left ventricular end-diastolic volume index, left ventricular end systolic volume index, left ventricular diastolic early and late filling speed ratio), myocardial injury markers (troponin I, troponin-T, CK - MB), inflammation index (hs-CRP, TNF alpha), the incidence of major adverse cardiovascular events, the incidence of adverse events. （4）Study design: randomized controlled trial, RCT. （5）Publication language: Chinese and English.
- Study Type Included
- Randomized controlled trial, RCT.
- Condition Being Studied
- Coronary heart disease refers to the heart disease caused by myocardial ischemia, hypoxia or necrosis due to lumen stenosis, spasm or obstruction caused by coronary atherosclerosis. It can be seen that angina pectoris, myocardial infarction, arrhythmia, heart failure and so on. It is one of the most common cardiovascular diseases in clinic. Tanshinone IIA has many cardiovascular pharmacological activities, such as expanding coronary artery, increasing coronary blood flow, increasing myocardial contractility, anti-atherosclerosis and so on. Sodium tanshinone IIA sulfonate is mainly sulfonated by Tanshinone IIA. It is widely used in clinic as an adjuvant treatment for coronary heart disease, angina pectoris and myocardial infarction.
- Participant
- We will include patients with clearly diagnosed coronary heart disease, including unstable angina pectoris, acute myocardial infarction, stable angina pectoris and perioperative interventional patients.
- Animal
- Human Disease Modelled
- Intervention
- The treatment group was sodium tanshinone IIA sulfonate injection combined with conventional Western medicine treatment.
- Comparator Control
- The control group was conventional Western medicine treatment, without any Traditional Chinese Medicine/Proprietary Chinese Medicine preparation, with or without placebo. Conventional western medicine treatment is defined as western medicine treatment recommended in previous or current guidelines, including general treatment (such as oxygen inhalation, bed rest, ECG monitoring, etc.), western medicine [such as angiotensin converting enzyme inhibitors (ACEI), aspirin β Receptor blockers, lipid-lowering agents, nitrates, calcium channel blockers, etc.], interventional therapy, etc.
- Main Outcome
- 1) As for unstable angina pectoris, stable angina pectoris and perioperative interventional patients, the main outcomes are：clinical curative effect, angina pectoris curative effect, electrocardiogram curative effect, inflammation index (conventional CRP, hs-CRP, interleukin-6), incidence of major adverse cardiovascular events, incidence of adverse events. 2) As for acute myocardial infarction, the main outcomes are：inflammation index (hs-CRP, TNF alpha), the incidence of major adverse cardiovascular events, the incidence of adverse events. Measures of effect Relative risks for clinical curative effect, angina pectoris curative effect, electrocardiogram curative effect, incidence of major adverse cardiovascular events, the incidence of adverse events. Weighted mean difference for inflammation index.
- Outcome Measure
- Additional Outcome
- 1) As for unstable angina pectoris, stable angina pectoris and perioperative interventional patients, the additional outcomes are：attack frequency of angina pectoris, duration of angina pectoris, myocardial injury markers (troponin-I, CK, CK - MB) and blood rheology indexes (whole blood high shear viscosity, plasma viscosity, whole blood low shear viscosity, erythrocyte hematocrit, platelet maximum aggregation rate, fibrinogen), blood lipid indicators (TC, TG, HDL-L, LDL-L). 2) As for acute myocardial infarction, the additional outcomes are: heart pump function (left ventricular ejection fraction, left ventricular end-diastolic volume index, left ventricular end systolic volume index, left ventricular diastolic early and late filling speed ratio), myocardial injury markers (troponin I, troponin-T, CK - MB). Measures of effect Weighted mean difference for the additional outcomes.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Coronary Disease; Humans; Phenanthrenes; Randomized Controlled Trials as Topic; tanshinone II A sodium sulfonate
- Contact
- Xueyang Zeng [email protected]
- Organisational Affiliation
- Department of Epidemiology and Bio-statistics , School of Public Health, Peking University
- Funding Source
- This work was supported by grants from the National Key Research and Development Program of China (2017YFC1700402 to RZ). Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> 2017YFC1700402 to RZ
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-09-09
- Registration Date
- 2021-10-10
- Anticipated Start Date
- 2021-07-20
- Anticipated Completion Date
- 2021-12-31
- Title Cn
- 丹参酮IIA磺酸钠治疗冠心病的有效性和安全性：随机临床试验的系统评价和Meta分析
- Title En
- Effectiveness and safety of sodium tanshinone IIA sulfonate in patients with coronary heart disease: a systematic review and meta-analysis of randomized clinical trials
- Bilingual Status
- complete